EPS for Novo Nordisk A/S (NVO) Expected At $0.61

October 14, 2018 - By Marie Mckinney

Novo Nordisk A/S (NYSE:NVO) Logo

Analysts expect Novo Nordisk A/S (NYSE:NVO) to report $0.61 EPS on November, 7.They anticipate $0.01 EPS change or 1.61 % from last quarter’s $0.62 EPS. NVO’s profit would be $1.49 billion giving it 17.43 P/E if the $0.61 EPS is correct. After having $0.68 EPS previously, Novo Nordisk A/S’s analysts see -10.29 % EPS growth. The stock increased 2.38% or $0.99 during the last trading session, reaching $42.53. About 1.89M shares traded or 23.44% up from the average. Novo Nordisk A/S (NYSE:NVO) has risen 0.93% since October 14, 2017 and is uptrending. It has underperformed by 14.69% the S&P500.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $103.66 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 17.04 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

More notable recent Novo Nordisk A/S (NYSE:NVO) news were published by: Seekingalpha.com which released: “Novo’s once-weekly somapacitan on par with daily Norditropin in mid-stage study” on September 28, 2018, also Seekingalpha.com with their article: “Novo Nordisk lays off 400 staff in R&D unit” published on September 18, 2018, Seekingalpha.com published: “Lilly’s dual GIP and GLP-1 receptor agonist shows positive action in mid-stage T2D study; shares up 3% premarket” on October 04, 2018. More interesting news about Novo Nordisk A/S (NYSE:NVO) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 09, 2018 as well as Seekingalpha.com‘s news article titled: “Novo Nordisk: Time To Sell?” with publication date: October 09, 2018.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.